{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+sodium+succinate&page=17", "query": { "intervention": "Methylprednisolone sodium succinate", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 484, "total_pages": 49, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+sodium+succinate&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+sodium+succinate&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T05:29:30.549Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03593902", "title": "Cardiac Safe Transplants for Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Systemic Sclerosis", "Scleroderma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2018-05-17", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593902" }, { "nct_id": "NCT02169219", "title": "Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Granulomatosis With Polyangiitis", "Microscopic Polyangiitis" ], "interventions": [ { "name": "Glucocorticoids", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 20, "start_date": "2014-06", "completion_date": "2017-11-01", "has_results": true, "last_update_posted_date": "2021-06-25", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169219" }, { "nct_id": "NCT01875237", "title": "Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myeloma", "Myeloproliferative Diseases" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Stem Cell infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mini Methotrexate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "PROCEDURE" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2013-12-27", "completion_date": "2017-03-07", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875237" }, { "nct_id": "NCT01319981", "title": "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "VSLI", "type": "DRUG" }, { "name": "Solu-Medrol", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2013-03-05", "completion_date": "2020-11-11", "has_results": true, "last_update_posted_date": "2022-09-27", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319981" }, { "nct_id": "NCT05150704", "title": "MYTHS - MYocarditis THerapy With Steroids", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myocarditis Acute" ], "interventions": [ { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "saline solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Niguarda Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 288, "start_date": "2021-10-07", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 4, "location_summary": "San Diego, California • Houston, Texas • Charlottesville, Virginia + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05150704" }, { "nct_id": "NCT02049073", "title": "Prevention of Noise-induced Hearing Loss", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Noise-induced Hearing Loss" ], "interventions": [ { "name": "Zonisamide", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "18 Years to 30 Years" }, "enrollment_count": 0, "start_date": "2017-10-31", "completion_date": "2017-11-01", "has_results": false, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049073" }, { "nct_id": "NCT00436761", "title": "Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 20, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436761" }, { "nct_id": "NCT04371445", "title": "Dextenza in the Post-op Management of Vitreoretinal Surgeries", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Vitreoretinal Surgery", "Ocular Inflammation", "Post-operative Pain", "Post-Operative Inflammation" ], "interventions": [ { "name": "Dexamethasone Ophthalmic Insert", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% Oph Susp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-06-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04371445" }, { "nct_id": "NCT04826237", "title": "Oral Statins and Protection From Hearing Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sudden Sensorineural Hearing Loss" ], "interventions": [ { "name": "Statin", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 3, "start_date": "2023-02-09", "completion_date": "2025-10-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04826237" }, { "nct_id": "NCT00630253", "title": "Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi Anemia" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "59 Years", "sex": "ALL", "summary": "Up to 59 Years" }, "enrollment_count": 31, "start_date": "2000-02-17", "completion_date": "2020-10-10", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-14T05:29:30.549Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00630253" } ] }